Online inquiry

IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14315MR)

This product GTTS-WQ14315MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFL7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016215.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51162
UniProt ID Q9UHF1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14315MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5687MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ2953MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ10418MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ1087MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ14751MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ1733MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ15257MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ9445MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW